Genmab A (GMAB) financials: revenue, earnings and cash flow
Fiscal 2017–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Genmab A’s revenue went from $381M in fiscal 2017 to $3.7B in fiscal 2025, growth of about 33.0% a year.
Net income in fiscal 2025 was $963M, a net margin of 25.9%; the best year in this period was 2024 with $1.1B.
Over the twelve months to September 30, 2026, revenue was $4.3B and net income $729M.
Free cash flow was $1.1B in fiscal 2025 and positive in 3 of the 6 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | $4.3B | $3.7B | $3.1B | $2.4B | $807M | $464M | $381M |
| Gross profit | — | $3.5B | $3.0B | $2.4B | — | — | — |
| Operating income | — | $1.1B | $972M | $772M | — | — | — |
| Net income | $729M | $963M | $1.1B | $631M | — | — | — |
| EPS (diluted) | $1.17 | $1.54 | $1.82 | $1.01 | — | — | — |
| R&D | — | — | — | — | — | — | — |
| Revenue growth | — | +19.2% | +30.6% | +196.2% | +74.0% | +21.8% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $875M | $1.2B | $1.1B | $1.1B | — | — | — |
| Capital spending | -$32M | -$37M | -$27M | -$53M | — | — | — |
| Free cash flow | $843M | $1.1B | $1.1B | $1.0B | — | — | — |
| Dividends paid | — | $0 | $0 | $0 | — | — | — |
| Buybacks | — | — | — | — | — | — | — |
| Stock-based pay | — | $128M | $105M | $85M | — | — | — |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Cash | — | $1.7B | $1.4B | $2.2B | — | — | — |
| Debt | — | $5.3B | $0 | $0 | — | — | — |
| Equity | — | $5.8B | $5.1B | $4.7B | — | — | — |
| Total assets | — | $12.9B | $6.4B | $5.2B | — | — | — |
| Shares (diluted) | 624M | 624M | 624M | 624M | 624M | 624M | 624M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Gross margin | — | 93.6% | 95.4% | 98.6% | — | — | — |
| Operating margin | — | 28.6% | 31.1% | 32.3% | — | — | — |
| Net margin | 17.0% | 25.9% | 36.3% | 26.4% | — | — | — |
| FCF margin | 19.6% | 30.9% | 35.2% | 42.6% | — | — | — |
| ROIC | — | 7.7% | 16.2% | 12.7% | — | — | — |
| ROE | — | 16.5% | 22.1% | 13.5% | — | — | — |
Frequently asked questions
What is Genmab A’s annual revenue?
$3.7B in fiscal 2025 and $4.3B over the twelve months to September 30, 2026.
How much profit does Genmab A make?
Net income was $963M in fiscal 2025 (net margin 25.9%).
Is Genmab A’s revenue growing?
Yes: revenue rose 19.2% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.